A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

Completed · Phase 1

Conditions studied: RSV Infection, Drug Drug Interaction

In brief

The primary aim of this study is to assess the effect of EDP-323 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy adult participants.

Key facts

Study ID
NCT06917508
Run by
Enanta Pharmaceuticals, Inc
People needed
24
Starts
2025-03-13
Expected to finish
2025-06-13
Last updated by the study team
2025-07-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.